help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on June 17, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2008-0001
A more recent version of this article appeared on September 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/9/3455    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Kok, P.
Right arrow Articles by Pijl, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kok, P.
Right arrow Articles by Pijl, H.
Related Collections
Right arrow Female Endocrinology
Right arrow Obesity
Right arrow Neuroendocrinology and Pituitary

Submitted on January 2, 2008
Accepted on June 9, 2008

Short term treatment with bromocriptine improves impaired circadian GH secretion in obese premenopausal women

Petra Kok, Ferdinand Roelfsema, Marijke Frölich, Johannes van Pelt, A Edo Meinders, and Hanno Pijl*

Dept. of General Internal Medicine, Leiden University Medical Center, The Netherlands; Dept. of Endocrinology & Metabolic Diseases, Leiden University Medical Center, The Netherlands; Dept. of Clinical Chemistry, Leiden University Medical Center, The Netherlands

* To whom correspondence should be addressed. E-mail: h.pijl{at}lumc.nl.

Context. A profound reduction of spontaneous as well as stimulated GH secretion has been consistently observed in obesity. Dopamine promotes GH release through activation of dopamine D2 receptors (D2R). Dopamine D2R availability in the brain is reduced in obese humans in proportion to body adiposity. We hypothesized that impaired dopamine D2R signalling is mechanistically involved in the deficient GH secretion associated with obesity.

Objective. To test this hypothesis we studied the effect of short-term bromocriptine (a D2R agonist) treatment on spontaneous 24 h GH secretion in obese women, while body weight and caloric intake remained constant.

Design. Prospective, fixed order, cross-over study (2004).

Setting. Clinical Research Center LUMC

Participants. Eighteen healthy obese women (BMI 33.2 ± 0.6 kg/m2) were studied twice in the early follicular phase of their menstrual cycle.

Intervention(s). Eight days of treatment with bromocriptine (B) and placebo (Pl)

Main Outcome Measure(s). Blood was collected during 24 hours at 10-minute intervals for determination of GH concentrations. GH secretion parameters were calculated using deconvolution analysis.

Results. Short-term treatment with bromocriptine significantly enhanced diurnal GH secretion (Pl 121.4 ± 16.4 vs. B 155.4 ± 15.2 µg/Lvdl/24 hr, P = 0.01), whereas IGF-1 concentrations remained constant (Pl 22.4 ± 2.4 vs. B 21.8 ± 1.6 nmol/L, P = 0.928).

Conclusion. Activation of dopamine D2 receptors by bromocriptine favourably affects impaired nyctohemeral GH secretion in obese women. Reduced dopaminergic neuronal signalling might be involved in the pathogenesis of obesity associated hyposomatotropism.
Key words: Dopamine Agonists • Metabolic Syndrome X • Somatotrophs • Dopamine D2 Receptors






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society